11 hours ago
Anaplastic Thyroid Cancer Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 8+ Companies and 8+ Therapies
DelveInsight's, 'Anaplastic Thyroid Cancer Pipeline Insight 2025,' report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Anaplastic Thyroid Cancer pipeline landscape. It covers the Anaplastic Thyroid Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Anaplastic Thyroid Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Anaplastic Thyroid Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Anaplastic Thyroid Cancer Pipeline Outlook
Key Takeaways from the Anaplastic Thyroid Cancer Pipeline Report
In June 2025, M.D. Anderson Cancer Center announced a phase II trial studies how well autologous tumor infiltrating lymphocytes LN-145 (LN-145) or LN-145-S1 works in treating patients with ovarian cancer, triple negative breast cancer (TNBC), anaplastic thyroid cancer, osteosarcoma, or other bone and soft tissue sarcomas that do not respond to treatment (refractory) or that has come back (relapsed).
DelveInsight's Anaplastic Thyroid Cancer Pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline therapies for Anaplastic Thyroid Cancer treatment.
The leading Anaplastic Thyroid Cancer Companies such as Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics, Inc., Merck & Co, Iovance Biotherapeutics, Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb and others.
Promising Anaplastic Thyroid Cancer Pipeline Therapies such as Pembrolizumab, Lenvatinib, Nivolumab, Sorafenib (Nexavar,BAY43-9006), dabrafenib/trametinib, Sacituzumab govitecan, MLN0128, Pembrolizumab (Keytruda), efatutazone, HLX208 and others.
Stay ahead with the most recent pipeline outlook for Anaplastic Thyroid Cancer. Get insights into clinical trials, emerging therapies, and leading companies with Anaplastic Thyroid Cancer @ Anaplastic Thyroid Cancer Treatment Drugs
Anaplastic Thyroid Cancer Emerging Drugs Profile
Sapanisertib: Takeda
Sapanisertib is a dual TORC 1/2 inhibitor that targets a key survival mechanism in KEAP1/NRF2-mutated tumor cells. These mutations are found in a considerable sub-population of patients across multiple solid tumor types. Sapanisertib has demonstrated promising single-agent activity in patients with relapsed/refractory NRF2-mutated squamous non-small cell lung cancer (NSCLC) and exhibits differential anti-tumor activity compared to rapalog inhibitors of TORC1 in NRF2-mutant squamous NSCLC in vivo models.
HLX208: Shanghai Henlius Biotech
BRAF V600E small-molecule inhibitor can be potentially used in the treatment of various solid tumors. HLX208 may be combined with the Company's proprietary EGFR or PD-1 targeted antibodies to enhance a high-quality, innovative and differentiated product portfolio for the treatment of various cancer types.
The Anaplastic Thyroid Cancer Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Anaplastic Thyroid Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Anaplastic Thyroid Cancer Treatment.
Anaplastic Thyroid Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Anaplastic Thyroid Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Anaplastic Thyroid Cancer market
Explore groundbreaking therapies and clinical trials in the Anaplastic Thyroid Cancer Pipeline. Access DelveInsight's detailed report now! @ New Anaplastic Thyroid Cancer Drugs
Anaplastic Thyroid Cancer Companies
Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics, Inc., Merck & Co, Iovance Biotherapeutics, Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb and others.
Anaplastic Thyroid Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Inhalation
Inhalation/Intravenous/Oral
Intranasal
Intravenous
Intravenous/ Subcutaneous
NA
Oral
Oral/intranasal/subcutaneous
Parenteral
Subcutaneous
Anaplastic Thyroid Cancer Products have been categorized under various Molecule types such as
Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Recombinant protein
Small molecule
Stem Cell
Vaccine
Unveil the future of Anaplastic Thyroid Cancer Treatment. Learn about new drugs, Anaplastic Thyroid Cancer Pipeline developments, and key companies with DelveInsight's expert analysis @ Anaplastic Thyroid Cancer Market Drivers and Barriers
Scope of the Anaplastic Thyroid Cancer Pipeline Report
Coverage- Global
Anaplastic Thyroid Cancer Companies- Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics, Inc., Merck & Co, Iovance Biotherapeutics, Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb and others.
Anaplastic Thyroid Cancer Pipeline Therapies- Pembrolizumab, Lenvatinib, Nivolumab, Sorafenib (Nexavar, BAY43-9006), dabrafenib/trametinib, Sacituzumab govitecan, MLN0128, Pembrolizumab (Keytruda), efatutazone, HLX208 and others.
Anaplastic Thyroid Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Anaplastic Thyroid Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Anaplastic Thyroid Cancer Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Anaplastic Thyroid Cancer Companies, Key Products and Unmet Needs
Table of Contents
Introduction
Executive Summary
Anaplastic Thyroid Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Anaplastic Thyroid Cancer – DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Drug name: Company name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Sapanisertib: Takeda
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
AIC100: AffyImmune Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Anaplastic Thyroid Cancer Key Companies
Anaplastic Thyroid Cancer Key Products
Anaplastic Thyroid Cancer- Unmet Needs
Anaplastic Thyroid Cancer- Market Drivers and Barriers
Anaplastic Thyroid Cancer- Future Perspectives and Conclusion
Anaplastic Thyroid Cancer Analyst Views
Anaplastic Thyroid Cancer Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
